Cart
sales@molnova.com
McN3716
CAS No. 69207-52-9
McN3716( Methyl palmoxirate | NSC359682 )
Catalog No. M21897 CAS No. 69207-52-9
Inhibition of brain mitochondrial β-oxidation by McN3716 (Methyl palmoxirate, MEP) significantly reduces the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 922 | In Stock |
|
| 10MG | 1140 | In Stock |
|
| 25MG | 1511 | In Stock |
|
| 50MG | 1841 | In Stock |
|
| 100MG | 2325 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 4650 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMcN3716
-
NoteResearch use only, not for human use.
-
Brief DescriptionInhibition of brain mitochondrial β-oxidation by McN3716 (Methyl palmoxirate, MEP) significantly reduces the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA.
-
DescriptionInhibition of brain mitochondrial β-oxidation by McN3716 (Methyl palmoxirate, MEP) significantly reduces the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, respectively, except for 15-HETE which was unaffected. There is a significant 34% reduction in the level of 6-keto-PGF1α, a byproduct of PGI2 (prostacyclin) in McN3716-treated rats. Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to vehicle.
-
In Vitro——
-
In VivoInhibition of brain mitochondrial β-oxidation by McN3716 (Methyl palmoxirate, MEP) significantly reduces the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, respectively, except for 15-HETE which was unaffected. There is a significant 34% reduction in the level of 6-keto-PGF1α, a byproduct of PGI2 (prostacyclin) in McN3716-treated rats. Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to vehicle.
-
SynonymsMethyl palmoxirate | NSC359682
-
PathwayOthers
-
TargetOther Targets
-
RecptorCarnitine palmitoyltransferase I (CPT-1)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number69207-52-9
-
Formula Weight298.46
-
Molecular FormulaC??H??O?
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(C1(CCCCCCCCCCCCCC)OC1)OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Picroside IV
Kutkoside is a mixture of iridoid glycosides namely, picroside II, Picroside IV and 6-ferulloylcatalpol, it may have antinociceptive and anti-inflammatory effects.
-
Ac2-12
Annexin/lipocortin 1-mimetic peptide; inhibits leukocyte extravasation. Reduces neutrophil adhesion and emigration, and promotes detachment of neutrophils from activated mesenteric endothelium in mice in vivo.
-
Nogo-66 (1-40)
Peptide fragment corresponding to residues 1 - 40 of Nogo-66, the domain of the myelin protein Nogo that inhibits axonal outgrowth. Acts as a competitive antagonist at the Nogo-66 receptor (NgR); blocks Nogo-66- and CNS myelin-induced inhibition of axonal growth, but does not reduce myelin-associated glycoprotein (MAG) inhibition of neurite outgrowth in vitro. Promotes regeneration of hemisected spinal axons and locomotor recovery following spinal injury in vivo.
